General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

BioNTech SE Sponsored ADR (BNTX) closed the last trading session at $112.76, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...